{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:04:27Z","timestamp":1790805867078,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T00:00:00Z","timestamp":1565136000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T00:00:00Z","timestamp":1565136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12882-019-1469-9","type":"journal-article","created":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T12:02:53Z","timestamp":1565179373000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Reduced membrane attack complex formation in umbilical cord blood during Eculizumab treatment of the mother: a case report"],"prefix":"10.1186","volume":"20","author":[{"given":"Subagini","family":"Nagarajah","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Tepel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Assing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaseelan","family":"Palarasah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lise Lotte Torvin","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotte Borg","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Bistrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,7]]},"reference":[{"key":"1469_CR1","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.semnephrol.2013.08.003","volume":"33","author":"D Kavanagh","year":"2013","unstructured":"Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol. 2013;33:508\u201330. \n                    https:\/\/doi.org\/10.1016\/j.semnephrol.2013.08.003\n                    \n                  .","journal-title":"Semin Nephrol"},{"key":"1469_CR2","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1371\/journal.pgen.0030041","volume":"3","author":"PF Zipfel","year":"2007","unstructured":"Zipfel PF, Edey M, Heinen S, J\u00f3zsi M, Richter H, Misselwitz J, Hoppe B, Routledge D, Strain L, Hughes AE, Goodship JA, Licht C, Goodship TH, Skerka C. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet. 2007;3:e41.","journal-title":"PLoS Genet"},{"key":"1469_CR3","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1053\/j.ajkd.2017.06.024","volume":"70","author":"C Duineveld","year":"2017","unstructured":"Duineveld C, Verhave JC, Berger SP, van de Kar NCAJ, Wetzels JFM. Living donor kidney transplantation in typical hemolytic uremic syndrome: a case series. Am J Kidney Dis. 2017;70:770\u20137. \n                    https:\/\/doi.org\/10.1053\/j.ajkd.2017.06.024\n                    \n                  .","journal-title":"Am J Kidney Dis"},{"key":"1469_CR4","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1111\/tri.13022","volume":"30","author":"CM Legendre","year":"2017","unstructured":"Legendre CM, Campistol JM, Feldkamp T, Remuzzi G, Kincaid JF, Lommel\u00e9 \u00c5, Wang J, Weekers LE, Sheerin NS. Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis. Transpl Int. 2017;30:1275\u201383. \n                    https:\/\/doi.org\/10.1111\/tri.13022\n                    \n                  .","journal-title":"Transpl Int"},{"key":"1469_CR5","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ki.2014.423","volume":"87","author":"C Licht","year":"2015","unstructured":"Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, Delmas Y, Douglas K, Furman RR, Gaber OA, Goodship T, Herthelius M, Hourmant M, Legendre CM, Remuzzi G, Sheerin N, Trivelli A, Loirat C. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015;87:1061\u201373. \n                    https:\/\/doi.org\/10.1038\/ki.2014.423\n                    \n                  .","journal-title":"Kidney Int"},{"key":"1469_CR6","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.trsl.2014.10.010","volume":"165","author":"EK Wong","year":"2015","unstructured":"Wong EK, Kavanagh D. Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Transl Res. 2015;165:306\u201320. \n                    https:\/\/doi.org\/10.1016\/j.trsl.2014.10.010\n                    \n                  .","journal-title":"Transl Res"},{"key":"1469_CR7","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/cpt.686","volume":"102","author":"E Volokhina","year":"2017","unstructured":"Volokhina E, Wijnsma K, van der Molen R, Roeleveld N, van der Velden T, Goertz J, Sweep F, Br\u00fcggemann RJ, Wetzels J, van de Kar N, van den Heuvel L. Eculizumab dosing regimen in atypical HUS: possibilities for individualized treatment. Clin Pharmacol Ther. 2017;102:671\u20138. \n                    https:\/\/doi.org\/10.1002\/cpt.686\n                    \n                  .","journal-title":"Clin Pharmacol Ther"},{"key":"1469_CR8","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jim.2010.09.024","volume":"362","author":"Y Palarasah","year":"2010","unstructured":"Palarasah Y, Skjodt K, Brandt J, Teisner B, Koch C, Vitved L, Skjoedt MO. Generation of a C3c specific monoclonal antibody and assessment of C3c as a putative inflammatory marker derived from complement factor C3. J Immunol Methods. 2010;362:142\u201350. \n                    https:\/\/doi.org\/10.1016\/j.jim.2010.09.024\n                    \n                  .","journal-title":"J Immunol Methods"},{"key":"1469_CR9","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/j.1365-2249.2011.04322.x","volume":"164","author":"Y Palarasah","year":"2011","unstructured":"Palarasah Y, Nielsen C, Sprog\u00f8e U, Christensen ML, Lillevang S, Madsen HO, Bygum A, Koch C, Skjodt K, Skjoedt MO. Novel assays to assess the functional capacity of the classical, the alternative and the lectin pathways of the complement system. Clin Exp Immunol. 2011;164:388\u201395. \n                    https:\/\/doi.org\/10.1111\/j.1365-2249.2011.04322.x\n                    \n                  .","journal-title":"Clin Exp Immunol"},{"key":"1469_CR10","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1093\/ndt\/gfw314","volume":"31","author":"A Servais","year":"2016","unstructured":"Servais A, Devillard N, Fr\u00e9meaux-Bacchi V, Hummel A, Salomon L, Contin-Bordes C, Gomer H, Legendre C, Delmas Y. Atypical haemolytic uraemic syndrome and pregnancy: outcome with ongoing eculizumab. Nephrol Dial Transplant. 2016;31:2122\u201330.","journal-title":"Nephrol Dial Transplant"},{"key":"1469_CR11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jri.2015.02.008","volume":"109","author":"E Segura-Cervantes","year":"2015","unstructured":"Segura-Cervantes E, Mancilla-Ramirez J, Zurita L, Paredes Y, Arredondo JL, Galindo-Sevilla N. Blood SC5b-9 complement levels increase at parturition during term and preterm labor. J Reprod Immunol. 2015;109:24\u201330. \n                    https:\/\/doi.org\/10.1016\/j.jri.2015.02.008\n                    \n                  .","journal-title":"J Reprod Immunol"},{"key":"1469_CR12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1586\/eci.12.99","volume":"9","author":"A Malek","year":"2013","unstructured":"Malek A. Role of IgG antibodies in association with placental function and immunologic diseases in human pregnancy. Expert Rev Clin Immunol. 2013;9:235\u201349. \n                    https:\/\/doi.org\/10.1586\/eci.12.99\n                    \n                  .","journal-title":"Expert Rev Clin Immunol"},{"key":"1469_CR13","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.imbio.2014.11.003","volume":"220","author":"RF Hallstensen","year":"2015","unstructured":"Hallstensen RF, Bergseth G, Fossc S, J\u00e6gera S, Gedde-Dahl T, Holt J, Christiansen D, Laub C, Brekke OL, Armstrong E, Stefanovic V, Andersenc JT, Sandliec I, Mollnes TE. Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn. Immunobiology. 2015;220:452\u20139.","journal-title":"Immunobiology"},{"key":"1469_CR14","unstructured":"Eculizumab (Soliris) ANNEX I Summary of product characteristics. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR.Product_Information\/human\/000791\/WC500054208.pdf\n                    \n                  ."},{"key":"1469_CR15","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/s41598-017-01087-7","volume":"7","author":"T Fukuzawa","year":"2017","unstructured":"Fukuzawa T, Sampei Z, Haraya K, Ruike Y, Shida-Kawazoe M, Shimizu Y, Gan SW, Irie M, Tsuboi Y, Tai H, Sakiyama T, Sakamoto A, Ishii S, Maeda A, Iwayanagi Y, Shibahara N, Shibuya M, Nakamura G, Nambu T, Hayasaka A, Mimoto F, Okura Y, Hori Y, Habu K, Wada M, Miura T, Tachibana T, Honda K, Tsunoda H, Kitazawa T, Kawabe Y, Igawa T, Hattori K, Nezu J. Long lasting neutralization of C5 by SKY59, a novel recycling antibody, is a potential therapy for complement-mediated diseases. Sci Rep. 2017;7:1080. \n                    https:\/\/doi.org\/10.1038\/s41598-017-01087-7\n                    \n                  .","journal-title":"Sci Rep"},{"key":"1469_CR16","volume-title":"DRUGDEX System","author":"CT Cheshire","year":"2012","unstructured":"Soliris [package insert], Cheshire CT. Alexion Pharmaceuticals, Inc; December 2012, Eculizumab. In: DRUGDEX System [Internet database. Greenwood Village: Thomson Reuters (Healthcare) Inc. Updated periodically; 2012."}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1469-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-019-1469-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1469-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T23:18:38Z","timestamp":1596669518000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-019-1469-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,7]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1469"],"URL":"https:\/\/doi.org\/10.1186\/s12882-019-1469-9","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,7]]},"assertion":[{"value":"20 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Approval was obtained from the regional committee (Data protection agency, Datatilsynet Region Syddanmark, number 17\/43602).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the person to publish information.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"307"}}